05:40 AM EDT, 10/15/2026 (MT Newswires) -- Truetide's (TRUE.L) Paraytec and VosBio completed phase 2 of a proposed six-month development program to evaluate a combined version of their technologies for early, non-invasive lung cancer detection, according to a Thursday filing. The phase 2 aimed to show that breath samples collected with VosBio's Universal Breath Collector contain recoverable extracellular vesicle-like particles, and that prepared samples can be measured consistently on Paraytec's fluorescence detection platform CX300. The results showed the technical feasibility of the combined workflow, which lays the foundation for phase 3. The London-listed technology-focused investor said the parties are finalizing a definitive collaboration agreement for the proposed research and development collaboration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.